Kava per Problemi di sonno legati all'ansia
A Evidenze Più grandi trial clinici mostrano in modo costante benefici significativi.Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'sleepcited.com';
const params = 'ingredient\u003Dkava\u0026condition\u003Danxiety\u002Drelated\u002Dsleep';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
In sintesi
Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
Key Study Findings
Case Reports
n=1
6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None
vs: None
Outcome: acute kava dermopathy with sebaceous gland necrosis
Effetto: None
None
Popolazione: 41-year-old Australian woman consuming kava for anxiety and insomnia
Case Reports
n=1
Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None
vs: None
Outcome: Resolution of kava withdrawal symptoms
Effetto: None
None
Popolazione: 45-year-old man with kava and kratom withdrawal
Other
Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract
vs: Placebo
Outcome: Tobacco cessation via stress/insomnia management
Effetto: None
None
Popolazione: Adult smokers (trial protocol)
Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None
vs: Vehicle control
Outcome: Acute oral toxicity, antinociceptive activity
Effetto: None
None
Popolazione: Animal model
Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None
vs: None
Outcome: Sleep quality improvement
Effetto: None
None
Popolazione: Insomnia patients
Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: Kava users
Key Statistics
23
Studi
2043
Partecipanti
↔
Mixed
A
Grado
Referenced Papers
The Medical journal …
2026
The American journal …
2025
1 citazioni
BMC complementary medicine …
2024
1 citazioni
Journal of clinical …
2022
27 citazioni
Cureus
2022
17 citazioni
Natural product research
2022
3 citazioni
Journal of psychosocial …
2022
2 citazioni
Combinatorial chemistry & …
2021
16 citazioni
Journal of clinical …
2020
17 citazioni
Chemical research in …
2019
6 citazioni
Natural Products from Single Plants as Sleep Aids: A Systematic Review.
Systematic Review
Journal of medicinal …
2018
19 citazioni
Sleep medicine reviews
2015
152 citazioni
Holistic nursing practice
2014
10 citazioni
Toxicokinetics of kava.
Other
Advances in pharmacological …
2011
79 citazioni
FASEB journal : …
2010
110 citazioni
Journal of psychopharmacology …
2005
176 citazioni
Medicine
2005
128 citazioni
Psychopharmacology
2005
36 citazioni
Integrative cancer therapies
2004
59 citazioni
Human psychopharmacology
2003
45 citazioni
Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents.
Review
General hospital psychiatry
2002
38 citazioni
Phytotherapy research : …
2001
74 citazioni
Human psychopharmacology
2001
52 citazioni
[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract].
Case Report
Der Hautarzt; Zeitschrift …
1996
22 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- sleep:
- 120-250 mg kavalactones/day, 1-2 hrs before bed
Limite massimo: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | 6 weeks | Negative | 1 |
| None | -- | Positive | 1 |
| AB-free kava extract | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| not specified | -- | Positive | -- |
Momento migliore per l'assunzione: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Drowsiness and reduced coordination
- ⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
- ⚠ Skin rash (kava dermopathy) with chronic high-dose use
- ⚠ GI discomfort
Interazioni note
- ● Alcohol — increased hepatotoxicity risk and CNS depression
- ● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
- ● Benzodiazepines and sedatives — additive CNS depression
- ● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
- ● Levodopa and dopaminergic drugs — kava may reduce efficacy
Livello di assunzione massimo tollerabile: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Kava help with Problemi di sonno legati all'ansia?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Problemi di sonno legati all'ansia management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Problemi di sonno legati all'ansia?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Problemi di sonno legati all'ansia?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.
Related Evidence
Altri ingredienti per Problemi di sonno legati all'ansia
Kava per altre condizioni
References
- [1] Ali Abid et al.. Med J Aust. 2026. Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. doi:10.5694/mja2.70120 PubMed
- [2] William Bleifuss et al.. Am J Emerg Med. 2025. Severe kava withdrawal managed with phenobarbital. doi:10.1016/j.ajem.2025.06.016 PubMed
- [3] Chengguo Xing et al.. BMC Complement Med Ther. 2024. The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … doi:10.1186/s12906-024-04722-9 PubMed
- [4] Rita B Soares et al.. J Clin Med. 2022. An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. doi:10.3390/jcm11144039 PubMed
- [5] Kanika Verma et al.. Cureus. 2022. The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. doi:10.7759/cureus.28425 PubMed
- [6] Juliana Veloso Ferreira et al.. Nat Prod Res. 2022. Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. doi:10.1080/14786419.2021.1973459 PubMed
- [7] Deana Goldin et al.. J Psychosoc Nurs Ment Health Serv. 2022. Calm Down With Kava: What Clinicians Need to Know. doi:10.3928/02793695-20220523-02 PubMed
- [8] Ruhi Ali et al.. Comb Chem High Throughput Screen. 2021. Nutraceuticals for Sleep Disorders. doi:10.2174/1386207324666210121111446 PubMed
- [9] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
- [10] Pengcheng Wang et al.. Chem Res Toxicol. 2019. Enzymes and Pathways of Kavain Bioactivation and Biotransformation. doi:10.1021/acs.chemrestox.9b00098 PubMed
- [11] Jungyoon Kim et al.. J Med Food. 2018. Natural Products from Single Plants as Sleep Aids: A Systematic Review. doi:10.1089/jmf.2017.4064 PubMed
- [12] Matthew J Leach et al.. Sleep Med Rev. 2015. Herbal medicine for insomnia: A systematic review and meta-analysis. doi:10.1016/j.smrv.2014.12.003 PubMed
- [13] Stephanie Maxine Ross. Holist Nurs Pract. 2014. Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. doi:10.1097/HNP.0000000000000040 PubMed
- [14] Anthony Rowe et al.. Adv Pharmacol Sci. 2011. Toxicokinetics of kava. doi:10.1155/2011/326724 PubMed
- [15] Ping Zhou et al.. FASEB J. 2010. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. doi:10.1096/fj.10-163311 PubMed
- [16] David Wheatley. J Psychopharmacol. 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. doi:10.1177/0269881105053309 PubMed
- [17] Bradly P Jacobs et al.. Medicine (Baltimore). 2005. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. doi:10.1097/01.md.0000172299.72364.95 PubMed
- [18] Kazuaki Shinomiya et al.. Psychopharmacology (Berl). 2005. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. doi:10.1007/s00213-005-2196-4 PubMed
- [19] Keith I Block et al.. Integr Cancer Ther. 2004. Safety and efficacy of herbal sedatives in cancer care. doi:10.1177/1534735404265003 PubMed
- [20] Sheree Cairney et al.. Hum Psychopharmacol. 2003. Saccade and cognitive impairment associated with kava intoxication. doi:10.1002/hup.532 PubMed
- [21] Ka Fai Chung et al.. Gen Hosp Psychiatry. 2002. Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. doi:10.1016/s0163-8343(02)00210-4 PubMed
- [22] D Wheatley. Phytother Res. 2001. Kava and valerian in the treatment of stress-induced insomnia. doi:10.1002/ptr.840 PubMed
- [23] David Wheatley. Hum Psychopharmacol. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. doi:10.1002/hup.299 PubMed
- [24] R Süss et al.. Hautarzt. 1996. [Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. doi:10.1007/s001050050451 PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.